The march of immunotherapy continues at ESMO 2020September 15, 2020ImmunotherapyGenitourinary CancerGastroenterologyLung CancerPatient & Survivor CareRenal Cell CarcinomaPractice Management
Immunotherapy should not be withheld because of sex, age, or PSAugust 27, 2020ImmunotherapyLung CancerMelanomaPatient & Survivor CareBreast CancerGastroenterologyGenitourinary Cancer
FDA approves new indications for pembrolizumabJuly 1, 2020Patient & Survivor CareBreast CancerCNS/Brain CancerGastroenterologyGenitourinary CancerGynecologic CancerHead & Neck/Thyroid Cancers
Personalized cancer vaccine may enhance checkpoint inhibitor activityJune 25, 2020ImmunotherapyBreast CancerGastroenterologyGenitourinary CancerGynecologic CancerHead & Neck/Thyroid CancersMelanoma
FDA approves immunotherapy combo for liver cancerMarch 11, 2020GastroenterologyImmunotherapyGastrointestinal Cancer
Tumor neoantigenicity metric improves prediction of response to immunotherapyFebruary 22, 2020ImmunotherapyLung CancerRenal Cell CarcinomaMelanoma
Experts break down latest CAR T-cell advances in lymphomaJanuary 22, 2020Immuno-oncologyImmunotherapyLymphoma & Plasma Cell Disorders
New toxicity subscale measures QOL in cancer patients on checkpoint inhibitorsJanuary 11, 2020ImmunotherapyLung CancerMelanoma
CAR T cells produce complete responses in T-cell malignanciesJanuary 7, 2020Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersImmunotherapyImmuno-oncology
CAR T-cell therapy advances in CLLDecember 26, 2019Leukemia, Myelodysplasia, TransplantationImmuno-oncologyImmunotherapy
Inhibitor appears to strengthen anti-BCMA CAR T cells in myeloma patientsDecember 23, 2019ImmunotherapyLymphoma & Plasma Cell DisordersImmuno-oncology
Survival data reported from largest CAR T trial in B-cell lymphomaDecember 20, 2019Lymphoma & Plasma Cell DisordersDLBCLFollicular LymphomaImmuno-oncologyImmunotherapy
‘Real-world’ data show CAR T therapies are cost effectiveDecember 13, 2019Immuno-oncologyImmunotherapyPractice Management
